Press Releases

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

Financing led by Forbion and includes participation from ARCH Venture Partners and a broad syndicate of world-class investors New funds will advance product candidate for the treatment of alpha-1 antitrypsin deficiency (AATD) into clinical trials Josh Brumm, General Partner at Forbion, to join AIRNA Board of Directors Cambridge, MA, USA and Tübingen, Germany, July 31, 2024 […]

$

AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases

Advancing next-generation RESTORE+™ RNA editing platform based on pioneering research of founders Thorsten Stafforst and Jin Billy Li

$

Publications

Precision RNA base editing with engineered and endogenous effectors

Laura S Pfeiffer, Thorsten Stafforst. Nat Biotechnol. 2023 Sep 21. doi: 10.1038/s41587-023-01927-0.

$

Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, Wettengel J, Li JB, Stafforst T. Nat Biotechnol 2019, 37:133-138, doi: 10.1038/s41587-019-0013-6, PMID: 30692694.

$